Cargando…

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramacciotti, Eduardo, Aguiar, Valéria Cristina Resende, Júnior, Valter Castelli, Casella, Ivan Benaducce, Zerati, Antonio Eduardo, Fareed, Jawed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/ https://www.ncbi.nlm.nih.gov/pubmed/30486661 http://dx.doi.org/10.1177/1076029618812955

Ejemplares similares

Zika and Chikungunya Virus and Risk for Venous Thromboembolism
por: Ramacciotti, Eduardo, et al.
Publicado: (2019)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Tellor, Katie B, et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
por: Fareed, Jawed, et al.
Publicado: (2019)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
por: Fareed, Jawed, et al.
Publicado: (2011)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

A Prospective Study Evaluating Patterns of Responses to the Caprini Score to Prevent Venous Thromboembolism After Interventional Treatment for Varicose Veins
por: Grill, Marcelo Halfen, et al.
Publicado: (2022)

Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
por: Hara, Nobuhiro, et al.
Publicado: (2017)

The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement
por: Tafur, Alfonso, et al.
Publicado: (2019)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
por: Camporese, Giuseppe, et al.
Publicado: (2020)

Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care
por: Ceresetto, Jose Manuel
Publicado: (2016)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
por: De Caterina, Raffaele, et al.
Publicado: (2017)

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
por: Stacy, Zachary A., et al.
Publicado: (2016)

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study
por: Grifoni, Elisa, et al.
Publicado: (2022)

COVID-19 IN LATIN AMERICA: CONFLICTS, RESISTANCES AND INEQUALITIES
por: Agostoni, Claudia, et al.
Publicado: (2023)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data
por: Odajima, Suguru, et al.
Publicado: (2022)

A Case of Tuberculosis-related Cerebral Venous Sinus Thrombosis and Pulmonary Thromboembolism Successfully Treated with Edoxaban
por: Nishino, Koichi, et al.
Publicado: (2022)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report
por: Nakao, Satoshi, et al.
Publicado: (2019)

Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients
por: Otasevic, Vladimir, et al.
Publicado: (2022)

Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
por: Fuji, Takeshi, et al.
Publicado: (2015)

Cellular Indices and Outcome in Patients with Acute Venous Thromboembolism
por: Siddiqui, Fakiha, et al.
Publicado: (2022)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm
por: Mochimaru, Takao, et al.
Publicado: (2017)

Fiscal federalism in Latin America : from entitlements to markets
por: Wiesner Durán, Eduardo
Publicado: (2003)

Covid-19 vaccines and thromboembolic complications
por: Sobreira, Marcone Lima, et al.
Publicado: (2021)

A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™
por: Iversen, Patrick L., et al.
Publicado: (2023)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Open veins of Latin America : five centuries of the pillage of a continent /
por: Galeano, Eduardo, 1940-2015
Publicado: (1997)

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage
por: Shoji, Tetsuaki, et al.
Publicado: (2018)

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
por: Zalpour, Ali, et al.
Publicado: (2015)

Data analytics applications in Latin America and emerging economies
por: Rodriguez, Eduardo
Publicado: (2017)

Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pvfeljvv8prhslft24bnjdhh9s